Neomorphic mutations in isocitrate dehydrogenase (IDH1 and IDH2), each seen in 8–12% of AML cases result in an abnormal oncometabolite 2‐hydroxyglutarate, which leads to a hypermethylated genome with a resultant block in differentiation 72. The gene discussed is IDH2; the disease is acute myeloid leukemia.